Topical therapy plays an important role in the treatment of psoriasis. It is the gold standard in mild psoriasis cases and is also recommended in addition to UV and systemic therapy in cases of moderate to severe psoriasis. In this overview article we summarize the current therapeutic options, taking into account special localizations (scalp, facial, intertriginous/genital, or palmoplantar lesions) and situations (hyperkeratotic or inflammatory forms), as well as the therapy options during pregnancy and breastfeeding. In the initial phase, the combination of topical corticosteroids and vitamin D analogues has proven to be the therapy of choice, as well as monotherapy in each case. In maintenance therapy, fixed combination therapy is recommended once or twice a week.

Public-Private Partnership (PPP) is an organizational model of public service delivery in which a public partner joins with a private one for a joint delivery of a public service, creating added value for both parties in this “partnership”. From the point of view of the public partner, it decreases public expenditure, increases the quality and distribution of public services, and reduces agency costs. From the point of view of the private partner, the benefits are in achieving the planned rate of return, reducing sub-investment costs, reducing agency costs, and avoiding debt risk. There are numerous studies on the correlation between economic development and investment through PPP, which have led to this research. According to the legal framework in Bosnia and Herzegovina, which is composed of entity and cantonal laws, a subject of PPPs may also be construction, use, maintenance and management or reconstruction of property for the purposes of meeting public needs in the health service sector. The aim of the paper is to explore the legal and institutional assumptions of investing through the PPP model in Bosnia and Herzegovina health service sector and to make recommendations for improving the PPP situation in the health service sector. In addition to the introduction and conclusion, the paper is structured in three parts. The first part represents a concise theoretical framework in which the subject of the research is situated, the second part presents the state of affairs pertaining to investments in the health service sector, and the third part analyzes the current state of the use of this form of public service delivery in Bosnia and Herzegovina. The concluding section makes recommendations for improvements in terms of improving the investment through PPP in the sector of health care services.

Bosnia and Herzegovina, having an extremely complex state system and at the same time being a developing country and economy in transition with a commitment to membership in the European Union, faces numerous challenges in adapting national legislation to the acquis communautaire. One of the key segments of the introduction of European standards is the establishment of an effective mechanism for the protection of competition in legislative and institutional terms. With the adoption of the Competition Law in 2005, which brings new solutions and is largely in line with the acquis, Bosnia and Herzegovina has made a significant step forward from the previous state of legal irregularity in this important segment. However, sixteen years of the enforcement of the BiH Competition Law have shown certain shortcomings regarding the particular solutions contained in it. These shortcomings concern the part of the provision of the law that regulates procedural issues, but also the functioning of the authority responsible for the protection of competition in Bosnia and Herzegovina and it can be assumed that these are obstructive elements in response to the challenges of COVID-19 pandemic. In order to follow the international trends, companies in BiH have entered into a process of business digitalization, which, however, being accelerated due to COVID-19 pandemic, has created many challenges before the Council of Competition of BiH as the authority responsible for public enforcement of the competition law. The aim of this paper is to question the extent to which COVID-19 pandemic has affected the work of the Council of Competition BiH, as well as to address some of the particular issues it has faced before the pandemic, including growing market concentration, growing power of digital platforms, protectionism, consumer vulnerability and consequent loss of public confidence. In order to meet the set research goals, the first part of the paper will present an analysis of the legal solutions in the context of the legal and institutional aspect of competition protection and will provide an overview of the situation regarding the digitalization of business operations in Bosnia and Herzegovina. The second part of the paper will provide an analysis of the work of the Council of Competition of BiH with special reference to the period of declaring the pandemic COVID-19.

746 EJD, vol. 30, n◦ 6, November-December 2020 7. Hayami M, Fuzitani T. A case of benigh lymphocytoma found in the stroma of Bowen’s disease. Rinsho hihuka 1998; 52: 1130-3. 8. Vandaele R. Benign lymphocytoma (lymphadenoma) of the skin associated with Bowen’s disease. Arch Belg Dermatol Syphiligr 1957; 13: 494-9. 9. Maubec E, Pinquier L, Viguier M, et al. Vaccination-induced cutaneous pseudolymphoma. J Am Acad Dermatol 2005; 52: 623-9.

Introduction Faecal calprotectin (FC) is a routinely used marker for identifying and monitoring children with inflammatory bowel disease (IBD). This non-invasive test is useful for screening children with gastrointestinal symptoms to avoid unnecessary invasive procedures. In this study, we validated for the first time the performance of a fully automated particle-enhanced turbidimetric immunoassay (PETIA) on the VITROS® 5600 analyzer for measurement of FC in symptomatic children and adolescents. Materials and methods For performance validation of the PETIA (fCAL® turbo, Bühlmann Laboratories, Switzerland) on the VITROS® 5600 analyzer (Ortho Clinical Diagnostics, USA) limit of quantitation (LoQ), linearity, precision data and calibration curve stability were defined. Additionally, 95 faecal samples were measured using the PETIA, an enzyme-linked immunosorbent assay (ELISA; fCAL®, Bühlmann Laboratories, Switzerland) and a semi-quantitative lateral flow assay (Quantum Blue Reader®, Bühlmann Laboratories, Switzerland) for agreement evaluation. Results The LoQ for calprotectin using PETIA on the VITROS® 5600 analyzer was 21 µg/g. The linearity range was 20 - 2100 µg/g and the precision study showed a total coefficient of variation (CV) between 2.3% and 8.9%. The calibration curve was stable for 4 weeks. Using the clinical samples quantifiable by PETIA, ELISA and the semi-quantitative lateral flow assay, Passing-Bablok regression analysis and Bland-Altman plots showed good agreement. Conclusions Due to good performance characteristics and agreement with established methods, the fully automated PETIA on the routine chemistry analyzer VITROS® 5600 is a new analytical option for the rapid determination of FC.